N
NanoString Technologies
Provider of life science tools for translational research based on the nCounter® technology for single-molecule counting.
About NanoString Technologies
NanoString Technologies, now a part of Bruker Corporation, is a biotechnology company that specializes in spatial biology and molecular profiling. The company operates in the life sciences sector, focusing on providing advanced tools and solutions for researchers and clinicians. NanoString's primary offerings include spatial transcriptomics and proteomics, which are techniques used to study the expression of genes and proteins within the context of tissue architecture. This allows for a deeper understanding of diseases, particularly cancer, by examining how cells interact within their native environments.
NanoString serves a diverse range of clients, including academic research institutions, pharmaceutical companies, and clinical laboratories. These clients use NanoString's technology for various applications such as drug development, biomarker discovery, and single-cell research. The company's products are designed to accelerate scientific discovery and improve the human condition by providing high-resolution insights into biological processes.
The market NanoString operates in is highly specialized and rapidly growing, driven by the increasing demand for precision medicine and advanced diagnostic tools. The company's business model is based on selling its proprietary instruments, consumables, and software solutions. Additionally, NanoString offers services such as data analysis and certified service provider programs, which generate recurring revenue streams.
NanoString makes money through the sale of its high-tech instruments like the GeoMx Digital Spatial Profiler and the nCounter Analysis System. It also earns revenue from consumables required for these instruments, such as assay kits and reagents. Furthermore, the company provides specialized data analysis services and maintains a global network of certified service providers, adding another layer of revenue.
In summary, NanoString Technologies is a key player in the spatial biology market, offering cutting-edge tools for gene and protein analysis. Its innovative solutions are essential for advancing research in oncology, drug development, and other life sciences fields.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2003
- Headquarters
- Seattle, United States
- Listing
- IPO 2013
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- OPOVP Venture Partners
Threshold Ventures- ACAccelerator Capital
Series B and later10 investors entered at this stage
Clarus Ventures
Lysosomal Therapeutics
BioMed Ventures
GE Healthcare
Oxford Finance
Silicon Valley Bank
AllianceBernstein
GE Ventures
Morgan Stanley Expansion Capital- CLCRG LP
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
33 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about NanoString Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NanoString Technologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.